Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage* / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007275:Injections, Intravenous; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D011187:Posture; D011433:Propranolol / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage*
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D014665:Vasodilator Agents; D006830:Hydralazine; D008750:Methyldopa; D011433:Propranolol; D006145:Guanethidine